BILLERICA, Mass., Feb. 21, 2018 /PRNewswire/ -- Bruker
Corporation (NASDAQ: BRKR) today announced that Mr. Anthony L. Mattacchione, Chief Financial Officer
(CFO) and Senior Vice President of Bruker, has submitted his
resignation, effective as of March 16,
2018, in order to pursue other interests. Mr.
Mattacchione has informed us that he has accepted a position as
Chief Financial Officer of private-equity backed CDMO company
Albany Molecular Research, Inc., commencing in April 2018.
Mr. Mattacchione's resignation is not the result of any dispute
or disagreement with the Company, or any matter relating to the
Company's accounting practices or financial statements.
Mr. Mattacchione is expected to continue in his role as Bruker's
Chief Financial Officer until his departure from the Company, and
he will work during the next few weeks to ensure an orderly
transition of his responsibilities. Bruker intends to initiate a
search for Mr. Mattacchione's permanent successor. Moreover, Bruker
expects to appoint an interim Chief Financial Officer within
weeks.
Bruker today also announced the appointment of Gerald N. Herman to serve as Bruker's principal
accounting officer ('PAO'), effective immediately. Mr. Herman
joined Bruker in December 2016 as
Vice President and Corporate Controller, and will continue to serve
in that capacity following this PAO appointment. Mr. Herman
previously has served in senior executive positions with various
publicly traded companies, including as Corporate Vice President -
Clinical Operations of PAREXEL International from 2014 to
February 2016, and as Corporate Vice
President & Controller-Finance of PAREXEL from 2008 to
2013. Prior to 2008, Mr. Herman was Vice President-Corporate
Controller of Presstek, Inc. and also served in financial,
consulting and accounting roles at various organizations, including
as Senior Manager at Arthur Andersen LLP from 1979 to 1987. Mr.
Herman is a Certified Public Accountant and holds a MBA degree from
the University of Chicago, and a Master
of Science in Taxation from Bentley University.
Frank H. Laukien, Bruker's
President and CEO, commented: "I would like to thank Tony for doing
an outstanding job as our Chief Financial Officer over the last 3
years, and for his service to Bruker since joining us in 2013. We
are grateful for Tony's positive impact on Bruker, and wish him
continued success."
Dr. Laukien continued: "Bruker's financial guidance for 2018
remains unchanged, and our commitment to continued, multi-year
profitable growth is not affected. Bruker has developed solid
management processes, has an experienced executive leadership team,
and our finance management team has great depth and expertise."
Mr. Mattacchione said: "I am very proud of my accomplishments
with Bruker over the last five years, including three years as its
CFO. During this time, we completed Bruker's operational
transformation and generated meaningful shareholder value. I
believe Bruker is well-positioned to continue to create value for
years to come."
About Bruker Corporation (NASDAQ: BRKR)
For more than 55 years, Bruker has enabled scientists to make
breakthrough discoveries and develop new applications that improve
the quality of human life. Bruker's high-performance scientific
instruments and high-value analytical and diagnostic solutions
enable scientists to explore life and materials at molecular,
cellular and microscopic levels. In close cooperation with our
customers, Bruker is enabling innovation, improved productivity and
customer success in life science molecular research, in applied and
pharma applications, in microscopy and nanoanalysis, and in
industrial applications, as well as in cell biology, preclinical
imaging, clinical phenomics and proteomics research, microbiology
and molecular pathology research. For more information, please
visit: www.bruker.com.
Contact:
Miroslava
Minkova
Head of Investor Relations
Bruker Corporation
T: +1 (978) 663 – 3660, ext. 1479
E: miroslava.minkova@bruker.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/bruker-announces-resignation-of-chief-financial-officer-and-appointment-of-principal-accounting-officer-300601624.html
SOURCE Bruker Corporation